SCHEMBL13301965

SCHEMBL13301965

CC(C)(C)C(=O)C(N)CCC(N)=O

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX15 P16050 1/20 0.56
BLM P54132 1/20 0.56
PMP22 Q01453 1/20 0.56
KMT2A Q03164 1/20 0.56
DPP4 P27487 3/20 0.44
DPP9 Q86TI2 3/20 0.44
DPP8 Q6V1X1 2/20 0.44
GRM8 O00222 1/20 0.37
GRM6 O15303 1/20 0.37
GRIN2D O15399 1/20 0.37
GRIN3B O60391 1/20 0.37
GSR P00390 1/20 0.37
CYP1A2 P05177 1/20 0.37
GRIK1 P39086 1/20 0.37
GRM5 P41594 1/20 0.37
GRIA1 P42261 1/20 0.37
GRIA2 P42262 1/20 0.37
GRIA3 P42263 1/20 0.37
SLC1A3 P43003 1/20 0.37
SLC1A2 P43004 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15745581 1.00 ALOX15 (0.56) ALOX15BLMPMP22KMT2ADPP4
SCHEMBL16688100 0.83 ALDH1A1 (0.38) ALOX15BLMPMP22KMT2ADPP4
SCHEMBL21427150 0.83 CYP1A2 (0.58) ALOX15BLMPMP22KMT2ADPP4
SCHEMBL16017853 0.83 GRIK1 (0.37) ALOX15BLMPMP22KMT2ADPP4
SCHEMBL12420329 0.83 CYP1A2 (0.58) ALOX15BLMPMP22KMT2ADPP4
SCHEMBL12420333 0.83 ALDH1A1 (0.38) ALOX15BLMPMP22KMT2ADPP4
SCHEMBL16017791 0.83 GRIK1 (0.37) ALOX15BLMPMP22KMT2ADPP4
SCHEMBL21090568 0.79 GABRP (0.34) ALOX15BLMPMP22KMT2ADPP4
SCHEMBL24595704 0.78 CHRNB2 (0.40) ALOX15BLMPMP22KMT2ADPP4
SCHEMBL15334832 0.78 ENPEP (0.42) DPP4DPP9DPP8GRM8GRM6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230348493-A1 COMPOUND FOR ADJUSTING ACTIVITY OF NMDA RECEPTOR, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF BEIJING GREATWAY PHARMACEUTICAL TECHNOLOGY CO. LTD. (CN) 2023-11-02 US disclosed
US-20230348493-A1 COMPOUND FOR ADJUSTING ACTIVITY OF NMDA RECEPTOR, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF BEIJING GREATWAY PHARMACEUTICAL TECHNOLOGY CO. LTD. (CN) 2023-11-02 US disclosed
US-20100144655-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2010-06-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230348493-A1 COMPOUND FOR ADJUSTING ACTIVITY OF NMDA RECEPTOR, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF GRIN1, GRIN3A, GRIN2C ALOX15 741/4885BLM 3953/4885PMP22 447/4885
US-20100144655-A1 ORGANIC COMPOUNDS OAT, MAVS, HAVCR2 ALOX15 258/4885BLM 1397/4885PMP22 2304/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.